The potential of nanomedicine to provide therapeutic benefits over conventional drug formulations has been proven with a number of drugs on the market. Following the success of DOXIL®, a liposome-based doxorubicin formulation which improves pharmakocinetic profile, DIVERSA have developed a new lipidic nanoemulsion. In this post, we look at how it overcomes the barriers of solubility, permeability and intracellular delivery of small molecules, to help biomedical researchers to reach the preclinical stages. Available in Europe through Tebubio, see how DIVERSA’s new technology can redefine the medicinal chemistry/lead screening workflow.